Our previous cohort study found that higher levels of soluble VAP-1 were closely related to the increased occurrence of MACE in patients with coronary heart disease (CHD) (8), the pathogenic role of VAP-1 in atherosclerotic diseases and its potential as a therapeutic target have also been investigated in several basic research studies (7). This evidence concerns the gene AOC3 and coronary artery disorder.